Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
Harrow Health, Inc. (HROW)
Last harrow health, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding OneHarrow Initiative is Launched to Unify Branding under Harrow Patrick W. Sullivan Promoted to Serve as Harrow’s Chief Commercial Officer MELT-300 and MELT-210 Programs on Track for New Drug Application Filings Harrow’s ImprimisRx Settles Pending Regulatory Matters with the California Board of Pharmacy NASHVILLE, Tenn., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today reaffirmed its full-year 2025 revenue guidance of between $270-280 million, and highlighted continued execution across its commercial and development programs. The Company announced it is on track to double the VEVYE sales force by Memorial Day, expand IHEEZO in the office-based setting, and double its surgical
Show less
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow Health, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in CaliforniaBusiness Wire
- Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update [Seeking Alpha]Seeking Alpha
- Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]Yahoo! Finance
- How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
HROW
Earnings
- 11/10/25 - Beat
HROW
Sec Filings
- 2/2/26 - Form 4
- 2/2/26 - Form 3
- 2/2/26 - Form 8-K
- HROW's page on the SEC website